| Jonathan H Griner, MD | |
|
175 Martin Ave, Suite 125, Ephrata, PA 17522-1761 | |
| (717) 721-5700 | |
| (717) 715-1296 |
| Full Name | Jonathan H Griner |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 25 Years |
| Location | 175 Martin Ave, Ephrata, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023088051 | NPI | - | NPPES |
| 001955281 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD422243 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wellspan Ephrata Community Hospital | Ephrata, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wellspan Medical Group | 1951213115 | 1946 |
News Archive
CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.
In a recent study, restricting dietary fat led to body fat loss at a rate 68 percent higher than cutting the same number of carbohydrate calories when adults with obesity ate strictly controlled diets. Carb restriction lowered production of the fat-regulating hormone insulin and increased fat burning as expected, whereas fat restriction had no observed changes in insulin production or fat burning.
Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the fourth milestone payment of US$3.56 million from the Defense Advanced Research Projects Agency.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
A study conducted in the state of Washington and reported in The Journal of Pain showed that almost half of deaths attributed to prescription opioids were Medicaid recipients, and using multiple pharmacies to fill prescriptions is linked with opioid overdoses.
› Verified 3 days ago
| Entity Name | Wellspan Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750480299 PECOS PAC ID: 1951213115 Enrollment ID: O20040220000815 |
News Archive
CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.
In a recent study, restricting dietary fat led to body fat loss at a rate 68 percent higher than cutting the same number of carbohydrate calories when adults with obesity ate strictly controlled diets. Carb restriction lowered production of the fat-regulating hormone insulin and increased fat burning as expected, whereas fat restriction had no observed changes in insulin production or fat burning.
Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the fourth milestone payment of US$3.56 million from the Defense Advanced Research Projects Agency.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
A study conducted in the state of Washington and reported in The Journal of Pain showed that almost half of deaths attributed to prescription opioids were Medicaid recipients, and using multiple pharmacies to fill prescriptions is linked with opioid overdoses.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jonathan H Griner, MD 3421 Concord Rd, York, PA 17402-9001 Ph: (717) 721-5700 | Jonathan H Griner, MD 175 Martin Ave, Suite 125, Ephrata, PA 17522-1761 Ph: (717) 721-5700 |
News Archive
CSC's Leading Edge Forum today released a report that identifies a new wave of disruptive technologies that will reshape the delivery of healthcare. These new technologies will help control costs while improving health by ushering in an era of wellness, self-monitoring, increased and earlier detection of disease, and more effective treatments.
In a recent study, restricting dietary fat led to body fat loss at a rate 68 percent higher than cutting the same number of carbohydrate calories when adults with obesity ate strictly controlled diets. Carb restriction lowered production of the fat-regulating hormone insulin and increased fat burning as expected, whereas fat restriction had no observed changes in insulin production or fat burning.
Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it has received the fourth milestone payment of US$3.56 million from the Defense Advanced Research Projects Agency.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
A study conducted in the state of Washington and reported in The Journal of Pain showed that almost half of deaths attributed to prescription opioids were Medicaid recipients, and using multiple pharmacies to fill prescriptions is linked with opioid overdoses.
› Verified 3 days ago
Dr. Kristi L Dively, D.O. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1170 S State St, Ephrata, PA 17522 Phone: 717-859-8000 Fax: 717-859-6313 | |
Dr. Jaylaine Ghoubrial, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 175 Martin Ave Ste 125, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-721-5712 | |
Dr. Dirk Strasser, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 175 Martin Ave Ste 125, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-715-1296 | |
Sonia Shashank Shah, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 175 Martin Ave, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-721-5712 | |
Shivani Bista, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 175 Martin Ave Ste 125, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-715-1296 | |
Robin Woollens Lynn, CRNP Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 175 Martin Ave, Suite 125, Ephrata, PA 17522 Phone: 717-721-5700 Fax: 717-721-5712 |